Catheter Port Reversal in Citrate Continuous Veno-Venous Hemofiltration

被引:3
|
作者
Boer, Willem [1 ]
Van Tornout, Mathias [2 ]
Vander Laenen, Margot [1 ]
Engelen, Kim [1 ]
Meex, Ingrid [1 ]
Jorens, Philippe [3 ]
机构
[1] Ziekenhuis Oost Limburg ZOL, Dept Anesthesiol Intens Care Med Emergency Med &, Schiepsebos 6, B-3600 Genk, Belgium
[2] AZ Sint Jan Brugge Oostende AV, Dept Anesthesiol & Intens Care Med, Brugge, Belgium
[3] Univ Antwerp, Antwerp Univ Hosp, Dept Crit Care Med, LEMP, Edegem, Belgium
来源
KIDNEY INTERNATIONAL REPORTS | 2021年 / 6卷 / 11期
关键词
access recirculation; catheter dysfunction; continuous renal replacement therapy; regional citrate anticoagulation; ACCESS RECIRCULATION; HEMODIALYSIS;
D O I
10.1016/j.ekir.2021.08.006
中图分类号
R5 [内科学]; R69 [泌尿科学(泌尿生殖系疾病)];
学科分类号
1002 ; 100201 ;
摘要
Introduction: Knowledge of effects of catheter port reversal (CathPR), when blood is withdrawn from the venous port and returned via the arterial port, often used in dysfunctional catheters in renal replacement therapy, is limited in the setting of citrate continuous veno-venous hemofiltration (CVVH). Methods: In this open trial, post-filter ionized calcium (PfiCa), post-filter citrate concentration (PfCC), catheter recirculation, and solute clearance were measured before, during, and after 6 hours of CathPR, in well-functioning catheters. All other settings, including citrate settings, were left constant during the study. Results: Twenty-three patients were included. Mean PfiCa before CathPR of 0.36 mmol/L (SD 0.06) decreased to 0.31 (0.04) after 2 hours (P = 0.002), 0.31 (0.04) (P = 0.002) at 4 hours, and 0.31 (0.04) at 6 hours (P = 0.001). Return to normal increased mean PfiCa to 0.34 (0.06) (P = 0.006). Mean PfCC rose from 592 mg/L (SD 164) before CathPR to 649 mg/L (190) after 2 hours (P = 0.045), to 696 mg/L (192) after 4 hours (P < 0.001), and to 657 mg/L (214) after 6 hours (P = 0.018). Return to normal decreased mean PfCC to 598 mg/L (184) (P = 0.024). Mean recirculation increased during CathPR (from 4.3% [0-8.7] before to 13.8% [9.7-22.2], P < 0.001). Urea, potassium, and creatinine clearances dropped significantly, but calcium clearance was unaffected. Conclusion: CathPR caused a significant decrease in PfiCA and increase in PfCC. Calcium handling differs from other solutes because of increases caused in citrate concentration and subsequent effects on calcium chelation. In citrate CVVH, CathPR in dysfunctional catheters should be limited in time, with intensive follow-up.
引用
收藏
页码:2775 / 2781
页数:7
相关论文
共 50 条
  • [31] CEFTOLOZANE-TAZOBACTAM PHARMACOKINETICS IN A PATIENT ON CONTINUOUS VENO-VENOUS HEMOFILTRATION
    Oliver, Wesley
    Gonzales, Jeffrey
    Heil, Emily
    Mehrotra, Shailly
    Robinett, Kathryn
    Saleeb, Paul
    Nicolau, David
    CRITICAL CARE MEDICINE, 2015, 43 (12)
  • [32] Continuous veno-venous hemofiltration with regional citrate anticoagulation: A four-year single-center experience
    Cassina, Tiziano
    Mauri, R.
    Engeler, A.
    Giannini, O.
    International Journal of Artificial Organs, 2008, 31 (11): : 937 - 943
  • [33] Continuous veno-venous hemofiltration with regional citrate anticoagulation: A four-year single-center experience
    Cassina, T.
    Mauri, R.
    Engeler, A.
    Giannin, O.
    INTERNATIONAL JOURNAL OF ARTIFICIAL ORGANS, 2008, 31 (11): : 937 - 943
  • [34] The acid-base effect of changing citrate solution for regional anticoagulation during continuous veno-venous hemofiltration
    Egi, M.
    Naka, T.
    Bellomo, R.
    Langenberg, C.
    Li, W.
    Fealy, N.
    Baldwin, I.
    INTERNATIONAL JOURNAL OF ARTIFICIAL ORGANS, 2008, 31 (03): : 228 - 236
  • [35] A continuous veno-venous hemofiltration protocol with anticoagulant citrate dextrose formula A and a calcium-containing replacement fluid
    Ong, Song C.
    Wille, Keith M.
    Speer, Rajesh
    Tolwani, Ashita J.
    INTERNATIONAL JOURNAL OF ARTIFICIAL ORGANS, 2014, 37 (06): : 499 - 502
  • [36] Analysis of Leukocyte Recruitment in Continuous Veno-Venous Hemofiltration with Regional Citrate vs. Systemic Heparin Anticoagulation
    Margraf, Andreas
    Liu, Chang
    Kullmar, Mira
    Meersch, Melanie
    Rossaint, Jan
    Zarbock, Alexander
    CELLS, 2022, 11 (11)
  • [37] Effectiveness of continuous veno-venous hemofiltration in the treatment of severe acute pancreatitis
    Chen, Xuan
    Sun, Meifang
    Mao, Xiuhong
    Liu, Xiaoxia
    Sun, Weihe
    EXPERIMENTAL AND THERAPEUTIC MEDICINE, 2019, 17 (04) : 2720 - 2724
  • [38] Myoglobin clearance during continuous veno-venous hemofiltration with or without dialysis
    Nicolau, D
    Feng, YS
    Wu, AHB
    Bernstein, SP
    Nightingale, CH
    INTERNATIONAL JOURNAL OF ARTIFICIAL ORGANS, 1998, 21 (04): : 205 - 209
  • [39] PREDICTORS OF IN HOSPITAL MORTALITY IN PATIENTS ON CONTINUOUS VENO-VENOUS HEMOFILTRATION IN THE ICU
    Saqib, Amina
    Siddiqui, Abulhasan
    Jawalant, Modi
    Raja, MAsood
    El Sayegh, Suzanne
    Maniatis, Theodore
    CRITICAL CARE MEDICINE, 2015, 43 (12)
  • [40] Teicoplanin pharmacokinetics in critically ill patients on continuous veno-venous hemofiltration
    Bellmann, R.
    Falkensammer, G.
    Seger, C.
    Weiler, S.
    Kountchev, J.
    Joannidis, M.
    INTERNATIONAL JOURNAL OF CLINICAL PHARMACOLOGY AND THERAPEUTICS, 2010, 48 (04) : 243 - 249